Ratings for TScan Therapeutics (NASDAQ:TCRX) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback